Prelude Therapeutics reports interim Phase 1 data for PRT2527; plans to partner CDK9 program

Prelude Therapeutics Inc

PRT2527 monotherapy ORR 17.4% (4/23 evaluable); combination with zanubrutinib ORR 38.5% (5/13 evaluable).
CRs observed in DLBCL (monotherapy and combo) and MCL (combo); responses in patients with prior CAR-T therapy.
Most common TEAE: neutropenia (48%, grade≥3: 46%); one DLT of tumor lysis syndrome at 24 mg/m2 dose.
Prelude will seek a partner for PRT2527 to focus resources on SMARCA degrader programs.
Data presented at 66th ASH Annual Meeting on Dec 11, 2024; 46 patients safety-evaluable as of Sep 17, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.